Insider Transactions in Q1 2025 at Alkermes Plc. (ALKS)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,896
+11.76%
|
-
|
|
Feb 13
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
144,419
-41.44%
|
$5,054,665
$35.02 P/Share
|
|
Feb 13
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
144,419
+27.23%
|
$4,043,732
$28.26 P/Share
|
|
Feb 12
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
204,921
-50.88%
|
$6,557,472
$32.98 P/Share
|
|
Feb 12
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
199,196
+33.25%
|
$3,784,724
$19.69 P/Share
|
|
Feb 06
2025
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,399
-8.68%
|
$229,369
$31.39 P/Share
|
|
Feb 06
2025
|
Christian Todd Nichols SVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,565
+22.37%
|
-
|
|
Feb 06
2025
|
Richard F Pops Director and CEO, Alkermes plc |
SELL
Payment of exercise price or tax liability
|
Direct |
79,925
-5.83%
|
$2,477,675
$31.39 P/Share
|
|
Feb 06
2025
|
Richard F Pops Director and CEO, Alkermes plc |
BUY
Grant, award, or other acquisition
|
Direct |
190,640
+12.21%
|
-
|
|
Feb 06
2025
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
9,752
-4.92%
|
$302,312
$31.39 P/Share
|
|
Feb 06
2025
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
32,350
+14.03%
|
-
|
|
Feb 06
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,083
-19.17%
|
$467,573
$31.39 P/Share
|
|
Feb 06
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,393
+30.42%
|
-
|
|
Feb 06
2025
|
Blair Curtis Jackson EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,647
-5.54%
|
$330,057
$31.39 P/Share
|
|
Feb 06
2025
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,393
+15.18%
|
-
|
|
Feb 06
2025
|
Iain Michael Brown SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,514
-5.33%
|
$232,934
$31.39 P/Share
|
|
Feb 06
2025
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,565
+14.85%
|
-
|
|
Jan 30
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100,918
-69.5%
|
$3,229,376
$32.05 P/Share
|
|
Jan 30
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
97,632
+18.72%
|
$2,147,904
$22.7 P/Share
|